Details of the Drug

General Information of Drug (ID: )

Drug Name
Synonyms
#Ro5 Violations (Lipinski): 1	Molecular Weight (mw)
	Logarithm of the Partition Coefficient (xlogp)
	Rotatable Bond Count (rotbonds)
	Hydrogen Bond Donor Count (hbonddonor)
	Hydrogen Bond Acceptor Count (hbondacc)
ADMET Property	Absorption AUC The area under the plot of plasma concentration (AUC) of drug is 494-1277 mgh/L [1] Absorption Cmax The maximum plasma concentration (Cmax) of drug is 57.8-183.7 mg/L [1] BDDCS Class Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [2] Clearance The total plasma clearance of drug is 7.2-9.6 mL/h/kg [3] Elimination Daptomycin is excreted primarily by the kidneys, approximately 78% of an administered dose recovered in urine and only 5.7% recovered in feces [3] Half-life The concentration or amount of drug in body reduced by one-half in 30.51 +/- 6.51 hours (in hemodialysis patients) [3] Metabolism The drug is metabolized via the liver [3] MRTD The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.468 micromolar/kg/day [4] Unbound Fraction The unbound fraction of drug in plasma is 0.083% [5] Vd The volume of distribution (Vd) of drug is 0.1 L/kg [1] Water Solubility The ability of drug to dissolve in water is measured as 1000 mg/mL [2]
Cross-matching ID

References

1	Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD: Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003 Apr;47(4):1318-23. doi: 10.1128/aac.47.4.1318-1323.2003.
2	BDDCS applied to over 900 drugs
3	FDA Approved Drug Products: CUBICIN (daptomycin) injection
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds